A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

This publication has 38 references indexed in Scilit:

• Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy.
  Circulation Research, 1992
• Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
  Circulation, 1991
• Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival?
  Journal of the American College of Cardiology, 1991
• Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
  Circulation, 1990
• Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.
  Circulation, 1990
• The Structure of a Complex of Recombinant Hirudin and Human α-Thrombin
  Science, 1990
• Enhancing thrombolytic efficacy by means of “front-loaded” administration of tissue plasminogen activator
  Journal of the American College of Cardiology, 1989
• Biology of Recombinant Hirudin (CGP 39393): A New Prospect in the Treatment of Thrombosis
  Seminars in Thrombosis and Hemostasis, 1989
• Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.
  Circulation, 1989
• The Thrombolysis in Myocardial Infarction (TIMI) Trial
  New England Journal of Medicine, 1985